SLC4A4 Antibody

What is SLC4A4 and why is it important in cellular research?

SLC4A4 (also known as NBC1, NBCe1) is an electrogenic sodium/bicarbonate cotransporter that plays a crucial role in maintaining acid-base balance within cells. It functions as a transmembrane protein that transports bicarbonate ions across cell membranes coupled with sodium ions, with a Na⁺:HCO₃⁻ stoichiometry varying from 1:2 to 1:3 . This transporter is vital for:

• Regulating bicarbonate influx/efflux at basolateral membranes

• Maintaining intracellular pH homeostasis

• Supporting critical physiological functions in various tissues including kidney, pancreas, and airway epithelial cells

SLC4A4 is particularly important in research focused on acid-base disorders, cancer biology, and respiratory diseases, as it helps regulate the acidic tumor microenvironment (TME) that affects cancer progression, therapy resistance, and immune evasion .

Proper validation of SLC4A4 antibody specificity is critical for reliable research outcomes. A comprehensive validation approach includes:

• Positive and negative controls:

  • Use tissues or cells known to express SLC4A4 (kidney, pancreas) as positive controls

  • Include SLC4A4 knockout/knockdown samples when available

  • Commercial antibodies often report validated reactivity in specific tissues (e.g., HEK-293 cells, mouse kidney tissue)

• Blocking peptide experiments:

  • Pre-incubate the antibody with the immunogenic peptide before application

  • Signal disappearance confirms specificity, as demonstrated in Western blot analyses of rat brain lysate and mouse liver membranes

• Multiple detection methods:

  • Compare results across different techniques (WB, IHC, IF)

  • Consistent localization patterns (e.g., basolateral membrane staining in epithelial cells) support specificity

• Molecular weight verification:

  • Confirm the observed molecular weight matches the expected size (~121 kDa)

  • Be aware of potential post-translational modifications that may alter migration

• Cross-reactivity testing:

  • Evaluate antibody performance across species of interest (human, mouse, rat)

  • Consider sequence homology when extrapolating between species

What are the optimal tissue preparation methods for SLC4A4 immunohistochemistry?

Proper tissue preparation is critical for successful SLC4A4 immunohistochemistry:

• Fixation protocols:

  • Formalin-fixed paraffin-embedded (FFPE) sections work well with many SLC4A4 antibodies

  • For frozen sections, immersion fixation followed by free-floating sectioning has been successful in rat brain tissue

• Antigen retrieval methods:

  • Heat-induced epitope retrieval (HIER) with TE buffer at pH 9.0 is recommended

  • Alternative approach: citrate buffer at pH 6.0

  • For IHC-Paraffin applications, HIER pH 6 retrieval is specifically recommended for some antibodies

• Section thickness and processing:

  • Standard 5-7 μm sections are typically suitable

  • For airway epithelial studies, consider orientation to properly visualize the basolateral membrane localization

• Blocking and permeabilization:

  • Include appropriate blocking of endogenous peroxidases for IHC

  • For immunofluorescence studies, ensure adequate permeabilization for accessing intracellular epitopes

  • For antibodies targeting extracellular epitopes, permeabilization may be unnecessary for live cell labeling

• Counterstaining:

  • DAPI works effectively as a nuclear counterstain in fluorescence applications

  • Hematoxylin counterstaining provides good contrast in chromogenic IHC applications

How can I optimize SLC4A4 antibody performance in Western blot applications?

Optimization strategies for Western blot applications include:

• Lysate preparation:

  • For membrane proteins like SLC4A4, use lysis buffers containing non-ionic detergents (e.g., Triton X-100, NP-40)

  • Consider membrane fraction enrichment for improved signal

  • Kidney tissue and HEK-293 cells serve as reliable positive controls

• Protein loading and transfer:

  • Load 20-50 μg of total protein lysate

  • Use wet transfer systems for optimal transfer of high molecular weight proteins (~121 kDa)

  • Consider longer transfer times (overnight at low voltage) for complete transfer

• Dilution optimization:

  • Start with the recommended 1:500-1:1000 dilution range

  • Perform titration experiments if background is problematic

  • Use a 5% BSA blocking solution to minimize non-specific binding

• Detection systems:

  • Enhanced chemiluminescence (ECL) technique has been validated for SLC4A4 detection

  • For quantitative analysis, consider fluorescent secondary antibodies and digital imaging

• Troubleshooting common issues:

  • Multiple bands: May represent isoforms or post-translational modifications

  • No signal: Verify expression in sample, adjust antibody concentration

  • High background: Increase washing steps, adjust blocking conditions

What controls should be included when investigating SLC4A4 expression in cancer research studies?

When investigating SLC4A4 in cancer research, comprehensive controls are essential:

• Positive tissue controls:

  • Include kidney tissue as a well-established positive control

  • For cancer studies, pancreatic ductal adenocarcinoma (PDAC) tissues show strong SLC4A4 expression in epithelial ductal cells

• Negative controls:

  • Primary antibody omission controls to assess secondary antibody specificity

  • Isotype controls to evaluate non-specific binding

  • Tissues known not to express SLC4A4

• Expression manipulation controls:

  • SLC4A4 knockdown (shSLC4A4) or knockout cells are valuable for antibody validation

  • Genetic inhibition models provide essential controls for phenotypic studies

  • Pharmacological inhibition using S0859 (SLC4A4 inhibitor) can complement genetic approaches

• Normal-tumor paired samples:

  • Compare SLC4A4 expression between matched normal and tumor tissues

  • Assess correlation with tumor grade and stage

  • In prostate cancer, for example, low-grade cancers show higher SLC4A4 expression compared to high-grade disease

• Methodological controls:

  • Multi-method validation (combine WB, IHC, IF, and IF/ICC)

  • Quantitative RT-PCR to correlate protein with mRNA expression

  • Single-cell RNA-sequencing data to identify cell type-specific expression patterns

How does SLC4A4 inhibition affect tumor microenvironment acidity and immune response?

Recent research has revealed important connections between SLC4A4 function, tumor microenvironment (TME) acidity, and immune responses:

• Effects on tumor acidity:

  • SLC4A4 inhibition in cancer cells mitigates TME acidosis through:

    • Bicarbonate accumulation in extracellular space

    • Decreased lactate production by cancer cells

    • Reduced glycolysis

• Immune response modulation:

  • In PDAC-bearing mice, SLC4A4 targeting:

    • Improves T cell-mediated immune responses

    • Breaches macrophage-mediated immunosuppression

    • Inhibits tumor growth and metastases

• Synergy with immunotherapy:

  • Slc4a4 targeting combined with immune checkpoint blockade:

    • Overcomes immunotherapy resistance

    • Prolongs survival in experimental models

• Mechanistic pathway:

  • In normal conditions, SLC4A4 contributes to TME acidification

  • Acidic TME promotes immunosuppression and tumor progression

  • SLC4A4 inhibition reverses this process by normalizing pH and enhancing anti-tumor immunity

These findings suggest SLC4A4 represents a promising therapeutic target to unleash antitumor immune responses, particularly in cancers like pancreatic ductal adenocarcinoma that are typically resistant to immunotherapy approaches .

What are the most effective strategies for detecting SLC4A4 localization in polarized epithelial cells?

Detecting SLC4A4 localization in polarized epithelial cells requires specialized approaches:

• Immunofluorescence optimization for polarized cells:

  • Use confocal microscopy for precise subcellular localization

  • Include co-staining with membrane markers for basolateral (e.g., Na⁺/K⁺-ATPase) and apical (e.g., CFTR) membranes

  • Incorporate cytoskeletal markers (e.g., acetylated tubulin) to identify specific cell types

• Three-dimensional reconstruction:

  • Z-stack imaging to visualize the complete cell architecture

  • Orthogonal views to confirm basolateral versus apical localization

  • In human airway tissues, SLC4A4 shows intracellular and basolateral membrane staining in epithelial cells that also stain positively for acetylated-tubulin

• Tissue-specific considerations:

  • For kidney: SLC4A4 shows strong cytoplasmic/membranous positivity in tubules

  • For pancreas: Strong membranous positivity in intercalated ducts

  • For airway epithelium: Preferential expression in ciliated cells with basolateral localization

• Live cell imaging applications:

  • Extracellular epitope-targeting antibodies (e.g., ANT-075) can label the cell surface of live intact cells

  • This approach has been validated in rat PC12 pheochromocytoma cells

• Electron microscopy techniques:

  • Immunogold labeling for ultrastructural localization

  • Particularly useful for precise membrane domain identification

How can SLC4A4 antibodies be used to investigate bicarbonate transport mechanisms in cellular pH regulation studies?

SLC4A4 antibodies can be powerful tools for investigating bicarbonate transport mechanisms:

• Functional correlation studies:

  • Combine antibody-based detection of SLC4A4 expression with functional pH measurements

  • In fully differentiated human airway epithelial cells, SLC4A4 inhibition induces acidification of airway surface liquid and reduces capacity to recover from acid load

• Live cell pH imaging:

  • Monitor intracellular pH using fluorescent indicators (e.g., BCECF)

  • Correlate pH changes with SLC4A4 expression and localization

  • Compare wild-type cells with SLC4A4 knockdown/knockout models

• Bicarbonate transport assays:

  • Measure ¹⁴C-labeled bicarbonate flux in cells with defined SLC4A4 expression

  • Assess changes following genetic or pharmacological manipulation of SLC4A4

  • Investigate Na⁺-dependent versus Na⁺-independent components of transport

• Interaction with regulatory partners:

  • Co-immunoprecipitation to identify protein complexes

  • SLC4A4 activity is regulated through interaction with carbonic anhydrase II, IV, and IX

  • Immunofluorescence co-localization with potential regulatory partners

• Pharmacological manipulation:

  • Use SLC4A4 inhibitor S0859 to block transport activity

  • Correlate changes in transport with protein expression and localization

  • In airway epithelial cells, S0859 decreases ASL pH under resting conditions and prevents forskolin-induced increases in ASL pH

How can SLC4A4 antibodies contribute to drug discovery for colorectal cancer?

SLC4A4 antibodies play critical roles in drug discovery for colorectal cancer:

• Target validation:

  • Confirm SLC4A4 expression and localization in colorectal cancer tissues

  • Correlate expression with clinical outcomes and prognosis

  • Low SLC4A4 expression correlates with increased lymph node and distant metastasis in CRC

• Screening assay development:

  • Develop cell-based assays for high-throughput compound screening

  • Western blot analysis using validated SLC4A4 antibodies can assess protein levels following treatment

  • Immunofluorescence can evaluate changes in subcellular localization

• Compound efficacy assessment:

  • Evaluate drug candidates identified through computational approaches

  • The compound DB07991 ((5R)-N-[(1r)-3-(4-hydroxyphenyl)butanoyl]-2-decanamide) shows promising binding affinity and stability with SLC4A4

  • Molecular dynamics simulations revealed strong protein-ligand interactions, suggesting potential therapeutic value

• Mechanism of action studies:

  • Determine how compounds affect SLC4A4 expression, localization, and function

  • Investigate downstream signaling pathways

  • SLC4A4 may regulate partial epithelial-mesenchymal transition phenotypes critical for cancer cell migration and invasion

• Companion diagnostic development:

  • SLC4A4 antibodies could be developed as companion diagnostics to identify patients likely to respond to SLC4A4-targeting therapies

  • Standardized IHC protocols would need validation in clinical specimens

What are the methodological considerations when using SLC4A4 antibodies in studies of airway epithelial pH regulation?

Studies of airway epithelial pH regulation using SLC4A4 antibodies require specific methodological considerations:

• Appropriate airway model systems:

  • Primary human airway epithelial cells (hAECs) cultured at air-liquid interface

  • Mouse tracheal epithelial cultures

  • Bronchial epithelial cell lines (e.g., Calu-3)

• SLC4A4 expression verification:

  • Confirm SLC4A4 expression in airway models

  • RT-PCR and Western blot analysis confirm expression in primary hAECs

  • Immunolocalization shows basolateral membrane staining in ciliated epithelial cells

• Functional correlation with pH measurements:

  • Combine SLC4A4 expression studies with pH measurements

  • Airway surface liquid (ASL) pH measurements using pH-sensitive fluorescent dyes

  • Intracellular pH (pHi) monitoring to assess acid-base regulation

• Experimental design for bicarbonate transport:

  • Ussing chamber experiments to measure transepithelial bicarbonate transport

  • Assessment of responses to stimulation (e.g., forskolin-induced CFTR activation)

  • SLC4A4 inhibition significantly decreases ASL pH under resting conditions and prevents forskolin-induced increases in ASL pH

• Disease model applications:

  • Slc4a4-null mice show a lung phenotype characterized by mucus accumulation and reduced mucociliary clearance

  • This phenotype resembles cystic fibrosis-like airway disease, highlighting the importance of SLC4A4 in bicarbonate secretion and airway function

How can researchers differentiate between SLC4A4 isoforms using currently available antibodies?

Differentiating between SLC4A4 isoforms presents specific challenges for researchers:

• Isoform-specific detection strategies:

  • Select antibodies raised against N-terminal regions where isoforms differ

  • Five isoforms of NBC1 are produced by alternative splicing, with isoforms 1 and 2 being the most studied

  • Isoform 2 is mainly expressed in kidney proximal tubules, while isoform 1 is expressed in pancreas and corneal endothelium

• PCR-based verification:

  • Complement antibody studies with RT-PCR using isoform-specific primers

  • In mouse airway epithelial cells, various SLC4 family members (Slc4a4, Slc4a5, Slc4a7, Slc4a8, Slc4a10) and specific Slc4a4 isoforms were detected using this approach

• Western blot analysis:

  • Resolve closely migrating isoforms using gradient gels

  • The N-terminus of isoform 1 contains multiple phosphorylation sites for PKA, PKC, and CK II, potentially affecting migration

  • Careful sample preparation to maintain post-translational modifications

• Immunoprecipitation approach:

  • Use pan-SLC4A4 antibodies for IP followed by isoform-specific detection

  • Mass spectrometry for unambiguous identification of isoforms

• Expression pattern analysis:

  • Tissue-specific expression patterns can help identify isoforms

  • Kidney: predominantly expresses isoform 2

  • Pancreas and corneal endothelium: predominantly express isoform 1

  • Compare expression patterns with known isoform distributions